Thymidylate synthase inhibitors as anticancer agents: From bench to bedside

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 52, Issue 1, 2003, Pages

  Chu, Edward ^a,b   Callender, Marc A ^a,b   Farrell, Michael P ^a,b   Schmitz, John C ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

5 Fluorouracil; Antifolates; Cancer chemotherapy; Drug resistance; Thymidylate synthase

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CAPECITABINE; CELL DNA; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GLYCINE HYDROXYMETHYLTRANSFERASE; GS 7904L; GW 1843; METESIND GLUCURONATE; NOLATREXED; NUCLEOSIDE DERIVATIVE; PEMETREXED; PLEVITREXED; RALTITREXED; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CANCER RESISTANCE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DNA SYNTHESIS; DRUG EFFICACY; DRUG FATALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; FEVER; FOLATE METABOLISM; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; INDOLES; NEOPLASMS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0041825123     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (89)

1. Andrake M, Guild N, Hsu T, Gold L, Tuerk C, Karam J (1988) DNA polymerase of bacteriophage T4 is an autogenous translational repressor. Proc Natl Acad Sci USA 85:7942
2. Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855
3. Belani C, Aqarwala S, Johnson J, Cohn A, Bernstein J, Langer C, Jones V, White C, Lob K, White D, Chew T, Johnston A, Clendeninn N (1997) A phase II trial of Thymitaq (AG337) in patients with squamous cell carcinoma of the head and neck (abstract 1381). Proc Am Soc Clin Oncol
4. Benson A, Poplin E, Douglas E (2000) ZD9331 plus topotecan in patients with refractory solid malignancies: a phase I dose-escalation study. Ann Oncol 11 [Suppl 4]:83
5. Bernardi A, Spahr PF (1972) Nucleotide sequence at the binding site for coat protein on RNA of bacteriophage R17. Proc Natl Acad Sci U S A 69:3033
6. Bobbio-Pallavicini E, Porta C, Moroni M, Spaghi A, Casagranda I, Nastasi G (1993) Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 5:52
7. Botwood N, James R, Vernon C, Price P (2000) Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer. Ann Oncol 11:1023
8. Brandt DS, Chu E (1997) Future challenges in the clinical development of thymidylate synthase inhibitor compounds. Oncol Res 9:403
9. Burris HA, Smetzer LA, Eckardt JR, Rodriguez GI, Rinaldi DA, Lampkin TA, Bigley JW, Von Hoff DD (1996) A phase I study of the novel thymidylate synthase inhibitor 1843U89 with and without high dose oral folate (abstract 1563). Proc Am Soc Clin Oncol
10. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P (2000) Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 356:373
11. Calvert AH, Alison DL, Harland SJ, Robinson BA, Jackman AL, Jones TR, Newell DR, Siddik ZH, Wiltshaw E, McElwain TJ (1986) A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 4:1245
12. Calvert AH, Hughes AN, Calvert PM, Plummer R, Highley M (2000) Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in phase I trial (abstract 1936). Proc Am Soc Clin Oncol
13. Calvete JA, Balmanno K, Taylor D, et al (1994) Preclinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor, AG337 (abstract 306). Proc Am Assoc Cancer Res
14. Carey J, Cameron V, de Haseth PL, Uhlenbeck OC (1983) Sequence-specific interaction of R17 coat protein with its ribonucleic acid binding site. Biochemistry 22:2601
15. Celio L, Bajetta E, Buzzoni R, Ferrari L, Martinetti A, Longaridini R, Marchano A, Ilardi C, Gentile A (2001) Efficacy and toxicity of pemetrexed disodium (Alimta) with folic acid (FA) in gastric cancer (abstract 660). Proc Am Soc Clin Oncol
16. Chu E, Allegra CJ (1996) Mechanisms of clinical resistance to 5-fluorouracil. In: Hait WN (ed) Drug resistance. Kluwer Academic Publishers, Boston, p 175
17. Chu E, Allegra CJ (1996) Antifolates. In: Chabner BA, Collins JM (eds) Cancer chemotherapy. Lippincott-Raven, New York, p 109
18. Chu E, Allegra CJ (1996) The role of thymidylate synthase as an RNA binding protein. Bioessays 18:191
19. Chu E, Zinn S, Boarman D, Allegra CJ (1990) Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 50:5834
20. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ (1991) Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 88:8977
21. Chu E, Voeller D, Koeller DM, Drake JC, Takimoto CH, Maley GF, Maley F, Allegra CJ (1993) Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci USA 90:517
22. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ (1993) Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 43:527
23. Chu E, Takimoto CH, Voeller D, Greta JL, Allegra CJ (1993) Specific binding of dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 32:4756
24. Chu E, Voeller DM, Morrison PF, Jones KL, Takechi T, Maley GF, Maley F, Allegra CJ (1994) The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA. J Biol Chem 269:20289
25. Chu E, Copur SM, Ju J, Chen TM, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F, Allegra CJ (1999) Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 19:1582
26. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR (1996) Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14:1495
27. Clendeninn NJ, Peterkin JJ, Webber S, Shetty BV, Koda RT, Leichman L, Leichman CG, Jeffers S, Muggia FM, O'Dwyer PJ (1994) AG-331, a "non-classical" lipophilic thymidylate synthase inhibitor for the treatment of solid tumors. Ann Oncol 4 [Suppl 5]:133
28. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16:2943
29. Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, Farris A, Ianniello GP, Lorusso V, Avallone A, Carteni G, Leo SS, Catalano G, De Lena M, Comella G (2000) Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5- fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol 11:1323
30. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G (1996) Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7:961
31. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D (1990) Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491
32. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2000) Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6:1378
33. Ercikan E, Banerjee D, Waltham M, Schnieders B, Scotto KW, Bertino JR (1993) Translational regulation of the synthesis of dihydrofolate reductase. Adv Exp Med Biol 338:537
34. Ercikan-Abali EA, Banerjee D, Waltham MC, Skacel N, Scotto KW, Bertino JR (1997) Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. Biochemistry 36:12317
35. Fu L, Minden D, Benchimol S (1996) Translational regulation of human p53 expression. EMBO J 15:4392
36. Goh BC, Ratain MJ, Bertucci D, Smith R, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Smith M, Averbuch S, Douglass E (2001) Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol 19:1476
37. Gold L (1988) Posttranscriptional regulatory mechanisms in Escherichia coli. Annu Rev Biochem 57:199
38. Heidelberger C (1981) On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep 65 [Suppl 3]:3
39. Heidelberger C, Chaudhuri NK, Danenberg P, Duchinsky R, Schnitzer RJ, Pleven E, Schener J (1957) Fluorinated pyrimidines: a new class of tumor-inhibitory compounds. Nature 179:663
40. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S, Wada H (2000) Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17:47
41. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M (1999) Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 19:5635
42. Jackman AL, Calvert AH (1995) Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6:871
43. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT (1997) Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3:911
44. John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, Thornton DE, Loehrer PJ (2000) Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 88:1807
45. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640
46. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407
47. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE (1997) Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89:308
48. Ju J, Chu E (2000) Translational regulation of 5-FU-induced p53 expression in human cancer RKO cells (abstract 5422). Proc Am Assoc Cancer Res
49. Ju J, Pedersen-Lane J, Maley F, Chu E (1999) Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 96:3769
50. Keyomarsi K, Samet J, Molnar G, Pardee AB (1993) The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 268:15142
51. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176
52. Lewis N, Scher R, Weiner LM, Engstrom P, Szarka C, Gallo J, Adams A, Litwin S, Kilpatrick D, Brady D, Meropol N (2000) Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed (abstract 757). Proc Am Soc Clin Oncol
53. Lin X, Parsels LA, Voeller DM, Allegra CJ, Maley GF, Maley F, Chu E (2000) Characterization of a cis-acting regulatory in the protein coding region of thymidylate synthase mRNA. Nucleic Acids Res 28:1381
54. Liu X, Reig B, Nasrallah IM, Stover PJ (2000) Human cytoplasmic serine hydroxymethyltransferase is an mRNA binding protein. Biochemistry 39:11523
55. Lokich J (1998) Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Huntingt) 12:19
56. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K (2000) Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: a multicenter phase II trial. Ann Oncol 11:435
57. Marsham PR, Wardleworth JM, Boyle FT, Hennequin LF, Kimbell R, Brown M, Jackman AL (1999) Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. J Med Chem 42:3809
58. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301
59. Mosner JT, Mummenbrauer C, Bauer G, Sczakeil F, Grosse F, Deppert W (1995) Negative feedback regulation of wild-type p53 synthesis. EMBO J 14:4442
60. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, Satoh A, Mizumoto T, Hamamoto R (1999) Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res 19:5621
61. O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM (1996) Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res 2:1685
62. O'Dwyer PJ, Nelson K, Thornton DE (1999) Overview of phase II trials of MTA in solid tumors. Semin Oncol 26:99
63. Pazdur R, Vincent M (1997) Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial (abstract 801). Proc Am Soc Clin Oncol
64. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653
65. Plummer R, Rees C, Judson I, Calvert H, Highley M, Trigo J, Jackman A, Smith R, Hithison M, Smith M (1999) Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days I and 8 with the cycle repeated every 3 weeks. Eur J Cancer 35:5285
66. Radar J, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass E (2000) Phase II trial of ZD9331 as third-line therapy for patients with ovarian carcinoma. Ann Oncol 11 [Suppl 4]:83
67. Raft I, Taylor GA, Balmanno K, Calvete JA, Newell DR, Lind MJ, Calvert AH (1994) A phase I study of the novel antifolate 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazole dihydrochloride (AG337) given by 24 hour intravenous continuous infusion. Ann Oncol 5 [Suppl 5]:131
68. Rinaldi DA (1999) Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 26:82
69. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17:1194
70. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322
71. Scagliotti G, Shin D, Kindler H, Johnson D, Keppler U (2001) Phase II study of Alimta single agent in patients with malignant pleural mesothelioma. Eur J Cancer 37:520
72. Scheithauer W, Kornek GV, Ulrich-Pur H, Penz M, Raderer M, Salek T, Haider K, Kwasny W, Depisch D (2001) Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a phase I-II trial. Cancer 91:1264
73. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA (1999) Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26:68
74. Schulz J, Douglass E (2000) ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial. Ann Oncol 11 [Suppl 4]:62
75. Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R, Wilson HR (1995) Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res 55:6117
76. Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J, Seymour L (1996) A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 74:479
77. Sobrero AF, Aschele C, Bertino JR (1997) Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15:368
78. Sorensen JM, Jordan E, Grem JL, Arbuck SG, Chen AP, Hamilton JM, Johnston P, Kohler DR, Goldspiel BR, Allegra CJ (1994) Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann Oncol 4 [Suppl 5]:132
79. Sotos GA, Grogan L, Allegra CJ (1994) Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 20:11
80. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH (1982) In vivo kinetics of thymidylate synthase inhibition in 5-fluororuacil-sensitive and -resistant murine colon adenocarcinoma. Cancer Res 42:450
81. Stuart K, Tessitore J, Rudy J, Clendinnen N, Johnston A (1999) A phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 86:410
82. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890
83. Theodoulou M, Llombart A, Cruciani G, Bloch R, Campos L, Tung N, Borges V, Perry M, Rowland K, Schuster M, Kneuper-Hall R, Hudis C (2000) Pemetrexed disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients (Pts) with prior anthracycline or anthracenedione and taxane treatment: phase II study (abstract 506). Proc Am Soc Clin Oncol
84. Trigo J, Rees C, Beale P, Mitchell F, Jackman A, Smith R, Hutchinson M, Smith M, Judson I (1999) Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks. Eur J Cancer 35:S286
85. Van der Wilt CL, Pinedo HM, Smit K, Peters GJ (1992) Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52:4922
86. Vogelzang N, Rusthoven J, Paoletti P, Denham C, Kaukel E, Ruffle P, Gatzemeier U, Boyer MJ, Emri S, Niyikiza C (2002) Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma (abstract 5). Proc Am Soc Clin Oncol
87. Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL, Aherne GW (2000) Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res 6:2538
88. Winter RB, Morrissey L, Gauss P, Gold L, Hsu T, Karam J (1987) Bacteriophage T4 regA protein binds to mRNAs and prevents translation initiation. Proc Natl Acad Sci USA 84:7822
89. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I (1996) ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 14:716